Alkylating Derivatives of Vitamin D Hormone for Prostate Cancer
Annual rept. 30 Sep 2008-29 Sep 2009
BOSTON UNIV MA
Pagination or Media Count:
The first significant achievement during this period includes strongly encouraging results of cellular studies with prostate cancer cells to demonstrate that a combination of 1,25-dihydroxyvitamin D3-3-bromoacetate 1,25OH2D3-3-BE and another compound named Largazole synergistically reduced the growth of these cells. Combination therapy in cancer is a well recognized modality in cancer-treatment. Therefore these results are highly significant in moving our drug 1,25OH2D3-3- BE, forward for prostate cancer-treatment. The second achievement involves development of a liposomal preparation of 1,25OH2D3-3-BE, and demonstration that this preparation is superior to naked drug both in in vitro and in vivo assays.
- Anatomy and Physiology
- Medicine and Medical Research